<DOC>
	<DOCNO>NCT02609269</DOCNO>
	<brief_summary>To prospectively evaluate utility genomic expression data tool well characterize tumor individual patient , understand genomic information individual patient undergo routine clinical test use population-level analysis improve treatment outcome .</brief_summary>
	<brief_title>Decipher Genomics Resource Information Database</brief_title>
	<detailed_description>Observational study involve release genome-wide expression data allow participate institution pair data clinical treatment outcome data patient Decipher test perform . Through collaboration , GRID database population use characterize genomics cancer discover new gene expression signature may useful expand current understanding biology disease .</detailed_description>
	<criteria>Decipher PostOp Clinical Indications Patient must achieve initial PSA nadir ( define undetectable PSA ≤0.1 ng/mL ) within 46 week , Pathological stage T2 disease positive surgical margin , Pathological stage T3 disease ( e.g. , extraprostatic extension , seminal vesicle invasion , bladder neck invasion ) , High Preoperative PSA ( e.g. , PSA ≥20 ng/mL ) , High Gleason grade disease ( e.g. , Gleason 7 10 Tertiary Gleason pattern 5 ) , Perineural , lymphovascular invasion , Lymph node involvement , Rising PSA Biochemical Recurrence Decipher Biopsy Clinical Indications • Any patient diagnose localized prostate cancer assess low , low , intermediate high risk NCCN guideline : 1 . Very low risk : T1c , Gleason score ≤ 6 , PSA &lt; 10ng/mL , few 3 prostate biopsy core positive , 50 % cancer core , PSA density &lt; 0.15 ng/mL/g 2 . Low risk : T1T2a , Gleason score ≤ 6 , PSA &lt; 10ng/mL 3 . Intermediate risk : T2bT2c , Gleason score 7 , PSA 1020 ng/mL 4 . High risk : T3a , Gleason score 810 , PSA &gt; 20 ng/mL 1 . Diagnosed metastatic disease ( M1 ) 2 . Metastatic Disease ( M+ ) prior surgery 3 . For salvage set patient : Metastatic Disease ( M+ ) PSA rise 4 . Received neoadjuvant prostate cancer treatment radical prostatectomy 5 . Required patient clinical data available evaluation eligibility criterion 6 . Any medical condition treat physician , study investigator designee determines exclude subject study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>